By Roger Longman
A month after July's top-management shake-up at Pfizer Inc. , one of that company's top clinical development executives was talking...
The $100 Million IND
An extraordinary series of high-value IND-stage deals could help to solve what has always been the intractable problem for biotechs: how to fund late-stage product development and simultaneously re-fill the early-stage pipeline. Still, it will be the rare biotech that can pull off this strategy--which requires INDs in the hottest areas of pharmaceutical development.